Tredje AP fonden decreased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 8.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 417,055 shares of the company’s stock after selling 38,634 shares during the period. Johnson & Johnson comprises 2.0% of Tredje AP fonden’s investment portfolio, making the stock its 3rd largest position. Tredje AP fonden’s holdings in Johnson & Johnson were worth $51,944,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in JNJ. Dynamic Technology Lab Private Ltd acquired a new position in shares of Johnson & Johnson during the first quarter valued at about $436,000. Arthur M. Cohen & Associates LLC raised its position in shares of Johnson & Johnson by 0.9% in the first quarter. Arthur M. Cohen & Associates LLC now owns 43,287 shares of the company’s stock valued at $5,396,000 after buying an additional 383 shares during the period. South Texas Money Management Ltd. raised its position in shares of Johnson & Johnson by 2.4% in the first quarter. South Texas Money Management Ltd. now owns 16,010 shares of the company’s stock valued at $1,994,000 after buying an additional 373 shares during the period. Svenska Handelsbanken AB publ raised its position in shares of Johnson & Johnson by 3.2% in the first quarter. Svenska Handelsbanken AB publ now owns 16,941 shares of the company’s stock valued at $2,110,000 after buying an additional 530 shares during the period. Finally, Private Advisor Group LLC raised its position in shares of Johnson & Johnson by 20.5% in the first quarter. Private Advisor Group LLC now owns 242,309 shares of the company’s stock valued at $27,117,000 after buying an additional 41,256 shares during the period. Institutional investors and hedge funds own 66.06% of the company’s stock.

Shares of Johnson & Johnson (NYSE JNJ) opened at 132.86 on Tuesday. The stock has a market cap of $357.90 billion, a price-to-earnings ratio of 22.48 and a beta of 0.78. The firm’s 50-day moving average price is $133.33 and its 200-day moving average price is $125.48. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $137.08.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.79 by $0.04. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The company had revenue of $18.84 billion during the quarter, compared to analysts’ expectations of $18.94 billion. During the same quarter last year, the company posted $1.74 EPS. The firm’s revenue was up 1.9% compared to the same quarter last year. On average, analysts forecast that Johnson & Johnson will post $7.18 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 12th. Shareholders of record on Tuesday, August 29th will be given a $0.84 dividend. The ex-dividend date of this dividend is Friday, August 25th. This represents a $3.36 annualized dividend and a yield of 2.53%. Johnson & Johnson’s dividend payout ratio is presently 56.76%.

ILLEGAL ACTIVITY WARNING: “Tredje AP fonden Sells 38,634 Shares of Johnson & Johnson (JNJ)” was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another site, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this story can be read at https://www.dailypolitical.com/2017/08/08/tredje-ap-fonden-sells-38634-shares-of-johnson-johnson-jnj.html.

Several research analysts have issued reports on the company. Credit Suisse Group restated a “buy” rating on shares of Johnson & Johnson in a research report on Friday. Zacks Investment Research lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. Alembic Global Advisors lowered Johnson & Johnson from a “neutral” rating to an “underweight” rating in a research report on Friday, July 21st. Atlantic Securities lowered Johnson & Johnson from a “neutral” rating to an “underweight” rating and set a $113.00 target price for the company. in a research report on Friday, July 21st. Finally, BTIG Research lowered Johnson & Johnson from a “neutral” rating to a “sell” rating and set a $110.00 target price for the company. in a research report on Friday, July 21st. Three equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $133.72.

In other news, VP Paulus Stoffels sold 102,692 shares of Johnson & Johnson stock in a transaction on Monday, July 24th. The shares were sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the completion of the sale, the vice president now directly owns 230,342 shares of the company’s stock, valued at approximately $30,667,733.88. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Dominic J. Caruso sold 82,591 shares of Johnson & Johnson stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the sale, the vice president now directly owns 226,693 shares of the company’s stock, valued at $30,993,466.96. The disclosure for this sale can be found here. Company insiders own 0.19% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.